Amphivena Therapeutics, Inc. — Form D/A
Amphivena Therapeutics, Inc. of SOUTH SAN FRANCISCO, CA, a company, filed a Form D amendment with the SEC on 2015-05-04. The offering totals $14.0M, of which $14.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2015-05-04
- Form: D/A
- Accession: 0001582186-15-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $14.0M
- Amount sold: $14.0M
- Investors: 4
- Date of first sale: 2013-07-11
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-200287
Issuer
- Name: Amphivena Therapeutics, Inc.
- CIK: 0001582186
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2012
- Address: 611 Gateway Blvd., SOUTH SAN FRANCISCO, CA, 94080
- Phone: (415) 994-6455
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Phil Gutry | Director | Baltimore, MD |
| Adi Hoess | Director | Heidelberg, 2M |
| FRANK MUHLENBECK | Director | SAN DIEGO, CA |
| Mark McDade | Director | South San Francisco, CA |
| Christian Richard | Director | Palo Alto, CA |
| Luke Evnin | Director | Watertown, MA |
| Eric Moessinger | Director | San Francisco, CA |
| Peter Van Vasselaer | Director | SOUTH SAN FRANCISCO, CA |
| Peter Van Vasselaer | Executive Officer | SOUTH SAN FRANCISCO, CA |
| Jeanmarie Guenot | Director | SOUTH SAN FRANCISCO, CA |
| Jeanmarie Guenot | Executive Officer | SOUTH SAN FRANCISCO, CA |
| Vinay Bhaskar | Director | San Francisco, CA |
| Florian Fischer | Director | San Francisco, CA |
Other filings by this issuer (4)
More